Abstract-For the specific analysis of endothelial NO synthase (eNOS) function in the coronary vasculature, we generated a mouse homozygous for a defective eNOS gene (eNOSϪ/Ϫ). Western blot as well as immunohistochemical staining revealed the absence of eNOS protein in eNOSϪ/Ϫ mice. Aortic endothelial cells derived from eNOSϪ/Ϫ mice displayed only background levels of NO x formation compared with wild-type (WT) cells (88 versus 1990 pmol
ndothelial NO synthase, also called type III NO synthase, is the major NOS isoenzyme that is widely expressed in endothelial cells throughout the vascular bed. It is generally accepted that endothelium-derived NO is an important factor in the control of basal vascular tone. 1 NO is also involved in receptor-mediated vasodilation in response to various agonists such as ACh, ATP, thrombin, bradykinin, and others. Through experiments using NOS inhibitors 2, 3 but also by use of genetically modified animals, 4, 5 it has been demonstrated that functional inactivation of eNOS activity results in hypertension. In addition to the control of vascular tone, NO inhibits platelet aggregation and leukocyte adhesion to the vessel wall as well as proliferation and migration of smooth muscle cells. Thus, eNOS is considered to play an important role in maintaining the antiatherogenic surface of the vessel wall. 6 In the heart, eNOS is expressed primarily in the coronary and endocardial endothelia. In addition, eNOS has been localized to cardiac myocytes and the specialized cells of sinus and AV nodes. 7 Here, eNOS is considered to be part of an intrinsic regulatory pathway that may control myocardial contractility in response to changes in heart rate and to mediate the accentuated antagonism of cholinergic stimulation. Neuronal (type I) NOS may also contribute to cardiac NO formation and was found to be localized in intracardiac neurons lining coronary vessels and in cells of the sinus and AV node. 7 Although more than one cell type in the heart can synthesize NO, the endothelium represents the major source of NO regulating coronary blood flow. Most studies indicate that basal formation of NO exerts a tonic dilator influence in the coronary circulation. 8 Pharmacological inhibition of NO synthesis reduces coronary flow in a variety of species, although this effect is quite variable.
9 -11 Shear stress is a major regulator of endothelial NO formation. Acute changes in shear stress regulate eNOS activity via intracellular pH and tyrosine phosphorylation. 12 In addition, chronic changes lead to modulation of eNOS expression via shear stress response elements in the eNOS promoter. 13 Thus, shear stress may be a key determinant linking alterations in coronary flow to changes in vascular resistance via modulation of eNOS formation.
In addition to the regulation of basal coronary tone, NO may also play a role in metabolic vasodilation in the heart. 14 Vascular resistance in reactive hyperemia 15, 16 or hypoxia 17 has been shown to be sensitive to NOS inhibition. Moreover, it has been postulated that the adenosine-induced vasodilation is mediated in part by NO. 18 To analyze the role of eNOS-derived NO on cardiovascular function, we constructed a knockout mouse with a disrupted eNOS gene. Here we report the first functional studies on coronary flow regulation in response to short-term ischemia and ACh-mediated vasodilation in a genetically defined model of eNOS deficiency.
Materials and Methods

Cloning of the Murine eNOS Gene and Construction of the Targeting Vector
The murine eNOS gene was cloned from a 129/Sv mouse genomic library established in bacteriophage DashII (Stratagene). Clones (1.8ϫ10 6 ) were screened with a 389-bp cDNA fragment of bovine endothelial NOS that was amplified from reverse-transcribed RNA from bovine aortic endothelial cells with the oligonucleotides 5Ј-TACGTGCCCTGCATCCTC-3Ј (forward primer) and 5Ј-CCCTCTGTCGCCAAGATG-3Ј (reverse primer). This region encodes the NADPH binding site of eNOS, which is essential for NOS activity. The exon structure of the 3Ј-end of eNOS was determined by sequencing 4.5 kb of genomic DNA. Exons 19 to 26 (numbering corresponding to the human eNOS gene 13 ) were identified in this region. Exon-intron boundaries were identical to those identified in the human eNOS gene. Sequence comparison of the assembled coding sequences revealed 87% identity with the human eNOS cDNA and 64% with the human neuronal NOS. For the construction of the targeting vector, a 0.8-kb EcoRI fragment containing exon 24 and the 5Ј part of exon 25 was replaced by the neomycin resistance gene (neoR). This results in deletion of the adenine nucleotide binding site of the NADPH binding site and of other sequences implicated in NADPH binding located in exon 24. 19 The targeting vector was constructed by placing a 0.8-kb EcoRI-Sca I fragment (short arm) on the 5Ј end and an 8-kb EcoRI fragment (long arm) 3Ј to the neoR gene. 20 The long arm was flanked by a herpes simplex thymidine kinase gene.
20
ES Cell Culture and Electroporation
E14 -1 cells, a subclone of the E14 ES cell line, were grown as described 21 on mitomycin-inactivated embryonic fibroblast feeder cells in medium containing 1000 U/mL leukemia inhibitory factor (Life Technologies). For electroporation, 10 7 cells were transfected with 50 g of linearized targeting vector by electroporation (Bio-Rad Gene Pulser set to 240 V, 500 F). Cells were plated onto neomycinresistant feeder cells and double-selected for G418 (350 g/mL) and gancyclovir (2 mol/L). Clones were isolated on day 7 to 10 after transfection and analyzed by PCR for proper targeting (eNOS primer 5Ј-CTGAGGACTGCACCTGTTCA-3Ј, neo primer 5Ј-GGAGAGGCTTTTTGCTTCCT-3Ј for 40 cycles of 1 minute at 94°C, 2 minutes at 55°C, and 2 minutes at 72°C). The genomic structure of the targeted eNOS locus was verified on ES cell and murine tail DNA by Southern blotting.
Targeted ES cells were microinjected into the blastocoel cavity of 3.5-day-old mouse blastocysts of strain C57BL/6. Injected blastocysts were implanted into pseudopregnant foster mothers (strain C57BL/ 6ϫCBA F1). Male chimeric mice were crossed to C57BL/6 females to test for germ line transmission. F1 heterozygous mutated animals were intercrossed to generate homozygous eNOSϪ/Ϫ mice. WT siblings obtained in these crosses were used as control animals in the phenotypical analysis of the eNOS mutation.
Western Blotting and Immunohistochemistry
Protein extracts were prepared by homogenization of mouse tissues in 50 mmol/L Tris (pH 7.5), 1 mmol/L EDTA, and 1 mmol/L PMSF. Extracts were centrifuged for 10 minutes at 10 000 rpm. Supernatant protein (200 g) was separated on 7.5% SDS polyacrylamide gels and electroblotted to nitrocellulose. eNOS was detected by monoclonal antibodies directed against the C-terminal end of human eNOS (Transduction Laboratories) according to the manufacturer's instructions. Protein bands were detected by horseradish peroxidase-labeled goat anti-mouse antibodies (Sigma) by use of the enhanced chemiluminescence detection system (Amersham).
For immunohistochemistry, organs were rapidly excised and frozen in OTC reagent (Miles). Sections (10 m) were cut on a cryostat and processed as described previously. 22 In brief, sections were mounted onto siliconized slides and fixed by immersion into 4% paraformaldehyde in 0.1 mol/L PB (pH 7.4) for 10 minutes at 4°C. Sections were rinsed twice (10 minutes) in PB, followed by the inhibition of endogenous peroxidase with 2% H 2 O 2 in PB for 30 minutes. Sections were rinsed twice in PB and twice, 10 minutes each, in TBS (50 mmol/L Tris-HCl, pH 7.4, 0.9% NaCl). Nonspecific binding was blocked by incubation in TBS containing 10% normal goat serum. For immunostaining, sections were incubated with primary polyclonal rabbit anti-eNOS antibodies directed against the C-terminal end of human eNOS (Transduction Laboratories) diluted 1:100 with TBS/1% normal goat serum for 24 hours at 4°C. Sections were rinsed three times for 5 minutes in TBS, and binding of primary antibody was visualized with a VectaStain anti-rabbit ABC kit (PK4001, Vector Laboratories) using 3Ј,3Ј-diaminobenzidine as a chromogene. Sections were briefly air-dried and counterstained with methyl green.
Blood Pressure Measurements
Mice were anesthetized with urethane (1.5 g/kg IP). The throat was incised, and a catheter of stretched PE tubing filled with PBS containing 50 U heparin/mL was inserted into the exposed right carotid artery. Pulsatile blood pressure was recorded on a Gould recorder. Data were recorded on an analog plotter and transferred simultaneously to a personal computer (one measurement per second). Mean blood pressures were calculated from the data collected for 10 minutes starting 30 minutes after onset of anesthesia. Animals were kept on a 37°C warming plate during data collection.
Isolation of Aortic Endothelial Cells and Determination of Nitrite/Nitrate Formation
For the isolation of aortic endothelial cells, aortas were prepared from WT and eNOSϪ/Ϫ mice, opened longitudinally, and placed with the intima onto collagen-coated six-well plates (type III collagen, Sigma Chemical Co). After 3 days, aortic tissues were removed, and endothelial cells that had emigrated from the vessel segments were grown to confluency (DMEM, 10% FCS, 1000 U endothelial cell growth factor/mL; Sigma). Cells were split 1:4, and eNOS expression was induced by shear stress applied by shaking of the plates for 6 hours at 120 rpm on a round shaker. Then, growth media were replaced by Krebs-Henseleit buffer, and cells were incubated for 3 hours at 37°C. NO x accumulating in the culture supernatant was detected by chemi-
Selected Abbreviations and Acronyms
L-NAME ϭ N -nitro-L-arginine methyl ester ACh ϭ acetylcholine eNOS ϭ endothelial NO synthase WT ϭ wild-type NOS ϭ nitric oxide synthase PCR ϭ polymerase chain reaction ES ϭ embryonic stem PB ϭ phosphate buffer TBS ϭ Tris-buffered saline luminescence with an NO analyzer (NOA280, Sievers Inc) after reduction of NO x to NO with VCl 3 according to the manufacturer's protocol.
For the determination of plasma nitriteϩnitrate levels, mice were fed with an NO 2 Ϫ /NO 3 Ϫ -free diet (Altromin). Blood was collected from ether-anesthetized animals by heart punctation. Blood coagulation was inhibited by the addition of 5 L 0.5 mol/L EDTA. Blood cells were sedimented by centrifugation in an Eppendorf microfuge (5000 rpm), and the plasma supernatant was collected. Samples were deproteinized by the addition of a twofold volume of ice-cold ethanol and centrifugation at 13 000 rpm for 30 minutes. Fifty-microliter aliquots were used for the determination of the NO x Ϫ concentration with the NO analyzer as described above.
Isolated Mouse Hearts
Mice were injected with 250 U heparin IP and anesthetized with urethane (1.5 g/kg). The hearts were rapidly excised and transferred for preparation of the aortic trunk to warm, oxygenated KrebsHenseleit buffer. The aorta was cannulated, and hearts were perfused in a nonrecirculating Langendorff mode at constant pressure (7 kPa, ie, 70 cm H 2 O) with a modified Krebs-Henseleit buffer containing (in mmol/L) NaCl 116, KCl 4.6, MgSO 4 1.1, NaHCO 3 24.9, CaCl 2 2.5, KH 2 PO 4 1.2, glucose 10, and EDTA 0.5 equilibrated with 95% O 2 and 5% CO 2 (pH 7.4, 37°C). Hearts were allowed to equilibrate for 30 to 40 minutes until a constant coronary flow was reached. Coronary flow was measured with a transit-time ultrasonic flowmeter located above the aortic cannula (Transonics). Acetylcholine and adenosine were infused into the aortic cannula for 180 to 300 seconds at infusion rates ranging from 0.2% to 1% of coronary flow.
Reactive hyperemia was elicited by interrupting coronary perfusion for 20 seconds. Maximal flow after reperfusion was recorded, and total flow, which represents the area under the flow curve, was determined by collecting and weighing the coronary effluent during the hyperemic flow, which lasted for Ϸ2 minutes. Adenosine release into the coronary effluent was determined by HPLC analysis essentially as described. 23 
Results
Disruption of the eNOS Gene by Gene Targeting
To inactivate the eNOS gene, sequences coding for the essential NADPH binding site (exons 24 and 25) were deleted (Fig 1) . Expression of the disrupted gene from exons 1 to 23 can be expected to result in the formation of an inactive enzyme because the NADPH-adenine-nucleotide binding site as well as other sequences implicated in NADPH binding are encoded by exon 24, 19 as well as by exon 26. 24 Exons 24 and 25 are located on a 0.8-kb EcoRI fragment, which was replaced by the neomycin resistance gene in the targeting vector pKO4 (Fig 1A) . The murine ES cell line E14 -1, 21 which is derived from the mouse strain 129/Ola, 25 was transfected with linearized targeting vector. Correctly targeted cells were identified by PCR, and the genomic structure was verified by Southern analysis. Three of 120 clones screened were correctly targeted and microinjected into C57BL/6 blastocysts. Male chimeras were crossed to C57BL/6 females to generate 129/ OlaϫC57BL/6 F1-eNOSϩ/Ϫ heterozygous offspring. These animals were subsequently bred to homozygosity. Analysis of the genomic structure of the eNOS locus of all three genotypes of the F2Ϫ offspring revealed that the eNOS locus was properly targeted and that the eNOS exons 24 and 25 had been deleted in genomic DNA of eNOSϪ/Ϫ mice (Fig 1B) .
Characterization of the eNOS Defect in eNOS؊/؊ Mice
Western blot analysis was performed with monoclonal antibodies directed against the C-terminal end of human eNOS. In heart, lung, kidney, and liver of WT mice, eNOS protein was detected (Fig 2) . However, in knockout mice, the 135-kD band, representing the full-length enzyme, was absent, which verified a correct targeting on the protein level.
Immunohistochemistry performed with the same antibody revealed intense staining of capillaries and small arteries in hearts (Fig 3a and 3c ) and thymus (Fig 3e) of WT animals. The staining was confined to endothelial cells. At the given level of sensitivity, eNOS expression could not be identified in cardiac myocytes. In contrast, endothelial cell layers in knockout mice did not react with the antibodies used (Fig 3b, 3d, and 3f) . High eNOS expression was also found in bronchial epithelia of WT mice but not in eNOSϪ/Ϫ animals (data not shown). Brain sections, stained for NADPH-diaphorase activity, a cytochemical marker for NOS activity, revealed the absence of endothelial staining in eNOSϪ/Ϫ mice, whereas WT controls were shown to contain stained intimal cell layers (data not shown).
To directly demonstrate the functional inactivation of eNOS, aortic endothelial cells were prepared and nitrite/ nitrate accumulation in the culture supernatant was determined (Fig 4) . WT endothelial cells were found to produce 1990Ϯ402 pmol NO x ⅐ h Ϫ1 ⅐ mg protein
Ϫ1
. This activity could be inhibited by L-NAME (100 mol ⅐ L
) by 89% to 231Ϯ34 pmol NO x ⅐ h Ϫ1 ⅐ mg protein
. In eNOSϪ/Ϫ cells, only background levels of nitrite accumulation (88Ϯ16 pmol NO x ⅐ h Ϫ1 ⅐ mg protein
) were detected, suggesting complete inactivation of the eNOS.
It was further analyzed whether loss of eNOS function influenced the plasma nitriteϩnitrate levels, the physiological oxidation products of NO. NO 2 /NO 3 levels amounted to 1.6Ϯ0.55 mol/L in plasma from WT and 0.74Ϯ0.07 mol/L in eNOSϪ/Ϫ mice (nϭ4 in each group).
Influence on Blood Pressure and Heart Rate
Pulsatile blood pressures were measured in WT and eNOSϪ/Ϫ mice under urethane anesthesia by a stretched PE 10 catheter inserted into the right carotid artery. Mean blood pressure was determined for 10 minutes starting 30 minutes after onset of anesthesia. WT mice displayed pressures of 107Ϯ8 mm Hg (ϮSD), whereas in eNOSϪ/Ϫ mice, blood pressure was elevated to 135Ϯ15 mm Hg (nϭ6 in each group, PϽ.001). Heart rate was determined in resting awake animals by means of ECG: whereas in WT mice, heart rate was 545Ϯ79 bpm, this value was significantly reduced to 494Ϯ81 bpm (nϭ9; PϽ.05) in eNOSϪ/Ϫ mice.
Analysis of Coronary Hemodynamics
To analyze the influence of the eNOS mutation on coronary hemodynamics, we compared flow responses in isolated Langendorff-perfused hearts from eNOSϪ/Ϫ mice with those in hearts from WT mice with and without NO synthase inhibition by L-NAME.
From the data summarized in the Table, it can be seen that L-NAME significantly reduced basal coronary flow in WT mice by 28%. In eNOSϪ/Ϫ hearts, however, basal coronary flow was not different from WT hearts. No differences in heart rate and in coronary venous release of adenosine were found between WT and eNOSϪ/Ϫ mice. The normalized heart weight was also unchanged.
In view of the proposed role of NO in reactive hyperemia, 15, 16 the flow response to short-term ischemia was analyzed. From the mean flow curves shown in Fig 5 and the summarized data shown in Fig 6, it is evident that inhibition of NOS activity in WT hearts by L-NAME reduced peak flow by 20% and repayment flow by 33% after 20 seconds of coronary occlusion. In contrast, the respective flow responses of WT and eNOSϪ/Ϫ hearts revealed only minor differences compared with the WT heart (Fig 5) . eNOSϪ/Ϫ hearts displayed a slightly higher maximal flow, but the flow repayment was not significantly different from WT hearts.
Adenosine release into the coronary venous effluents during the hyperemic phase amounted to 323.15Ϯ91.51 (SD, nϭ4) and 333.63Ϯ216.97 (SD, nϭ5) pmol ⅐ min Ϫ1 ⅐ g wet wt in the WT and eNOSϪ/Ϫ mice, respectively. In addition, the coronary response to adenosine, an endothelium-independent vasodilator, proved not to be different between the two groups when applied at concentrations of 250 nmol/L and 1 mol/L (data not shown).
Intracoronary infusion of ACh (500 nmol/L) induced a biphasic response in mouse hearts. As shown in the representative recordings (Fig 7) , an initial vasoconstriction was followed by substantial vasodilation in WT hearts. In eNOSϪ/Ϫ hearts, the initial flow decrease was much more pronounced than in WT hearts and was also of longer duration, whereas the extent of vasodilation was not affected. Comparison of the averaged data (Fig 8) revealed a flow decrease of Ϫ35% in WT and of Ϫ71% in eNOSϪ/Ϫ hearts. The subsequent AChinduced vasodilation reached the same level as in WT hearts. Acute inhibition of NOS activity by L-NAME in WT hearts significantly reduced (Ϫ36%) steady-state vasodilation but left the initial vasoconstriction unaltered (Fig 8) .
Because the ACh-induced vasodilation was unaffected in eNOSϪ/Ϫ hearts, we tested whether prostaglandins contributed to the flow response to ACh in the mouse heart. Inhibition of cyclooxygenase with diclofenac (2 mol ⅐ L Ϫ1 ) did not affect basal coronary flow in WT or eNOSϪ/Ϫ hearts. However, as shown in the representative recording in Fig 9, diclofenac abolished the dilatory action and ACh infusion caused sustained vasoconstriction (flow, Ϫ49%) (Fig 10) . In eNOSϪ/Ϫ hearts, the vasoconstriction was even more pronounced and resulted in a flow decrease by Ϫ71%. Also note that cessation of ACh infusion was followed by a substantial increase in coronary flow. This hyperemic flow response is most likely due to the ACh-induced hypoperfusion in the presence of diclofenac.
Discussion
A knockout mouse with a defective gene for eNOS was constructed for a specific analysis of eNOS function in the cardiovas- Western analysis of eNOS expression in lung, liver, kidney, and heart from WT and eNOSϪ/Ϫ mice. The band corresponding to the eNOS protein is indicated (135 kD). The molecular weight marker is shown beside the blot. In addition to detection of the eNOS band, the use of a monoclonal antibody resulted in the staining of a variety of unspecific bands. This was mainly due to the use of a secondary anti-mouse antibody that detected mouse serum proteins present in the tissue extracts. Because this background staining was most extensive for the murine IgG heavy chain (55 kD), only the part of the blot containing proteins ranging from 70 to 205 kD is shown. cular system. We decided to disrupt the NADPH binding site because the NOS reaction depends strictly on this cofactor. Exons 24 and 25 contain sequences crucial for NADPH binding. A cysteine corresponding to Cys-1048 of human eNOS is located in exon 24. A point mutation of this amino acid leads to a 90% decrease in enzymatic activity. 19 Exon 25 encodes a conserved sequence motif, which binds to the adenine moiety of NADPH. Within this sequence is located another conserved cysteine (Cys 1114), which also leads to a drastic decrease of eNOS activity when mutated. 19 DNA sequences encoding these elements were deleted from the mouse genome. In addition, because of the insertion of the neomycin resistance gene, the C-terminal end of eNOS encoded by exon 26 can be assumed to be absent from a truncated protein synthesized from exons 1 to 23. Recently, Xie et al 24 demonstrated that this exon contains a sequence element that is highly conserved among all known NOS isoforms. Functional analysis using inducible NOS revealed that this conserved sequence constitutes an essential part of the NADPH binding site in addition to the NADPH ribose and NADPH adenine binding sites identified before. Deletion of this element resulted in a complete loss of enzymatic activity.
Western analysis of protein extracts from different organs as well as immunocytochemistry using antibodies directed against the deleted C-terminal end of eNOS demonstrated eNOS expression in WT but not in eNOSϪ/Ϫ mice. Because our knockout strategy involved disruption of the 3Ј end of the eNOS gene, the expression of a truncated protein encoded by exons 1 to 23 cannot be ruled out.
Several lines of evidence demonstrate that the eNOS was functionally inactivated in our mice. (1) Cultured aortic endothelial cells from eNOSϪ/Ϫ mice displayed only background levels of NO x formation. (2) NADPH diaphorase staining, which depends on functional NOS, was absent from the endothelia of eNOSϪ/Ϫ mice. (3) eNOSϪ/Ϫ mice developed hypertension. (4) Plasma NO 2 Ϫ /NO 3 Ϫ levels were reduced by Ͼ50% in eNOSϪ/Ϫ mice, suggesting that eNOS activity contributes significantly to the total NO release.
In agreement with earlier reports by Huang et al 4 and Shesely et al, 5 who also demonstrated the development of hypertension for independently generated eNOS knockout mice, mean arterial blood pressure measured under urethane anesthesia in the present study was increased by 28 mm Hg, from 107 to 135 mm Hg, compared with WT mice. A similar increase was found by Huang et al, 4 who reported blood pressures of 81 and 110 mm Hg for their WT and eNOSϪ/Ϫ mice, respectively, measured under the same anesthesia.
Several studies in hypertensive patients have demonstrated an impaired vasodilation in response to cholinergic stimulation, implying that a defective L-arginine-NO pathway might be involved. 26, 27 However, controversy still exists as to whether this impairment is causative for or the consequence of hypertension. Of interest is a recent observation that offspring of essential hypertensive patients that were still normotensive were characterized by a defect in the NO pathway. This finding suggests that a genetic predisposition to hypertension might arise from a defective NO pathway. 28 Thus, eNOSϪ/Ϫ mice, now generated in three different laboratories, may represent a clinically relevant model system for the study of a genetically defined hypertension.
Surprisingly, despite hypertension, we found no cardiac hypertrophy in eNOSϪ/Ϫ mice. This is in contrast to studies in which long-term inhibition of NOS activity in the rat resulted in doubling of the cardiac weight index after 8 weeks of L-NAME administration. 3 Comparison of these results is difficult, however, because L-NAME inhibits all NOS isoforms. Whether lack of hypertrophy in eNOSϪ/Ϫ mice is due to NO-related changes in trophic factors remains to be elucidated.
In accordance with the results obtained by Shesely et al, 5 we found a reduced heart rate in awake eNOSϪ/Ϫ mice. Whether this bradycardia is a result of reflectory changes due to blood pressure elevation or involves a specific chronotropic action is at present unclear.
Coronary vasomotion is regulated by a large number of vasoactive factors, including NO, prostacyclin, endotheliumderived hyperpolarization factor, adenosine, endothelin, angiotensin II, K ϩ , and others. 29 Acute inhibition of NOS activity Heart rate, bpm 331Ϯ40 (14) ND 368Ϯ42 (11) Adenosine release, pmol ⅐ min Ϫ1 ⅐ g wet wt
Heart weight index, mg dry wt ⅐ animal wt revealed a contribution of basal NO release to the control of coronary vascular tone in most species analyzed, although the extent varied widely. 9 -11 Similarly, L-NAME decreased the basal coronary flow by 28% in WT mice. Thus, NO contributes substantially to the setting of the basal coronary vascular tone in mice as well. In eNOSϪ/Ϫ hearts, however, basal coronary flow did not differ from WT hearts, suggesting that other factors compensated for the loss of eNOS. There was also no difference in the coronary venous release of adenosine, making it rather unlikely that this vasoactive nucleoside may have compensated for the loss of NO in maintaining constant coronary flow. Also, the sensitivity of the coronary vessels to infused adenosine was not different between WT and eNOSϪ/Ϫ mice, ruling out the possibility that changes in adenosine receptor density and/or signal transduction may be involved.
Reactive hyperemia after brief periods of coronary occlusion is in part mediated by the concerted action of adenosine and NO. 16 However, activation of K ATP channels in reactive hyperemia may play a role as well. 30 In WT hearts, L-NAME substantially changed the flow response to short-term ischemia. Maximal and repayment flow were reduced after inhibition of NOS activity. In contrast, eNOSϪ/Ϫ hearts revealed no decrease in either maximal or repayment flow. Again, the adenosine release was identical in WT and eNOSϪ/Ϫ mice, suggesting that the loss of eNOS function was compensated for by a release of other mediators.
ACh causes coronary vasodilation by the combined activation of eNOS, the prostaglandin pathway, and endotheliumderived hyperpolarization factor. In addition, ACh can induce vasoconstriction when the endothelium is dysfunctional or high concentrations of ACh are applied. 31 Both actions are probably mediated by the activation of M3 muscarinergic receptors, which are located on both endothelial and smooth muscle cells. 32 However, the relative contribution of each of these mediators to the ACh-induced flow response varies considerably among species. Whereas in the guinea pig heart, ACh-induced vasodilation is dependent mainly on NO, 33 a concerted action of PGI 2 and NO was reported to mediate the response in the rabbit heart. 34 In the mouse heart, ACh induces an initial rapid vasoconstriction, which is evident at the beginning of the flow response, followed by a vasodilation, which dominates the flow in the steady state. Most likely, the extent of vasodilation represents the net result of both oppositely directed effects. In WT mice, acute inhibition of NOS activity by L-NAME reduced coronary vasodilation in response to ACh. Thus, as in other species, NO contributes to the ACh-induced vasodilation in the mouse heart. The initial vasoconstriction was left unchanged. In eNOSϪ/Ϫ mice, on the other hand, the steady-state flow response to ACh remained unaltered compared with the WT control. The initial vasoconstriction, however, was potentiated in eNOSϪ/Ϫ mice. Assuming that the steady-state vasodilation represents the net effect of vasoconstriction and vasodilation, this result implies that the dilatory component of the ACh effect was also augmented, because no changes in net vasodilation occurred. These findings demonstrate that there are important changes in the responsiveness of the coronary vasculature to ACh. Chronic loss of NO appears to have sensitized cholinergic signal transduction at the site of coronary resistance vessels. Alternatively, it is conceivable that vascular permeability to ACh and/or metabolism of ACh is altered in eNOSϪ/Ϫ mice.
The present findings clearly demonstrate that in WT mice, the ACh-induced vasodilation is mediated predominantly by prostaglandins. Inhibition of cyclooxygenase with diclofenac abolished vasodilation and resulted in sustained vasoconstriction. Thus, the contribution of NO to the ACh-dependent vasodilation, which was identified by use of L-NAME, was not sufficient to counteract the ACh-induced vasoconstriction. In the eNOSϪ/Ϫ mice, conversely, vasodilation was mediated exclusively by prostaglandins. Chronic loss of eNOS in the presence of pharmacologically inhibited prostaglandin synthesis resulted in severe vasoconstriction, which reduced coronary flow by 71%. Thus, most likely the lack of eNOS during ACh-mediated vasodilation was compensated for by an elevated release of prostaglandins in eNOSϪ/Ϫ hearts. This result does not contradict the findings of Huang et al, 4 who demonstrated lack of ACh response in isolated aortic segments of eNOSϪ/Ϫ mice. Rather, it emphasizes that the signal transduction pathway and mediators involved in the vascular response are profoundly different in the large conduit vessels compared with the small resistance vessels, which were examined in the present study. 
